FSD Pharma Inc. reported ongoing litigation related to former CEO Dr. Raza Bokhari's wrongful dismissal claims seeking C$30.2 million, which the corporation has counterclaimed as baseless; the latest court ruling on February 6, 2024, affirmed a previous arbitration award in favor of FSD, confirming the dismissal of Bokhari's claims and awarding the corporation additional costs.